scholarly journals Novel aspects of antiplatelet therapy in cardiovascular disease

2018 ◽  
Vol 2 (3) ◽  
pp. 439-449 ◽  
Author(s):  
Thomas Gremmel ◽  
Alan D. Michelson ◽  
Andrew L. Frelinger ◽  
Deepak L. Bhatt
Keyword(s):  
Cardiovascular Disease ◽  
Antiplatelet Therapy

Perioperative Management of Antiplatelet Therapy in Patients with Cardiovascular Disease

Orthopedics ◽  
2008 ◽  
Vol 31 (12) ◽  
pp. 1210-1213 ◽  
Author(s):  
Stephen J. Lemon ◽  
Jeremy D. Flynn ◽  
Steven P. Dunn
Keyword(s):  
Cardiovascular Disease ◽  
Antiplatelet Therapy ◽  
Perioperative Management

scholarly journals Antiplatelet Therapy in the Management of Cardiovascular Disease in Patients with CKD: What Is the Evidence?

2012 ◽  
Vol 8 (4) ◽  
pp. 665-674 ◽  
Author(s):  
Nishank Jain ◽  
S. Susan Hedayati ◽  
Ravindra Sarode ◽  
Subhash Banerjee ◽  
Robert F. Reilly
Keyword(s):  
Cardiovascular Disease ◽  
Antiplatelet Therapy

scholarly journals Role of antiplatelet therapy in cardiovascular disease II: Ischemic stroke

2004 ◽  
Vol 20 (11) ◽  
pp. 1845-1849
Author(s):  
Jeffrey J. Cavendish ◽  
Steven C. Cramer ◽  
Glenn D. Graham
Keyword(s):  
Cardiovascular Disease ◽  
Ischemic Stroke ◽  
Antiplatelet Therapy

scholarly journals Update of Antiplatelet Therapy in Patients Without Known Cardiovascular Disease

2018 ◽  
Vol 19 (4) ◽  
pp. 383-388
Author(s):  
Miloje Tomasevic ◽  
Srdjan Aleksandric ◽  
Sinisa Stojkovic
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Primary Prevention ◽  
Antiplatelet Therapy ◽  
Dual Antiplatelet Therapy ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Randomized Controlled ◽  
Artery Disease ◽  
Prevention Of Cardiovascular Disease

Abstract Platelet activation and aggregation play a critical role in thrombosis, a fundamental pathophysiologic event responsible for the acute clinical manifestations of atherothrombotic events such as acute coronary syndrome, myocardial infarction, ischemic stroke/transient ischemic attack and peripheral artery disease. Dual antiplatelet therapy (low-dose aspirin plus ADP-P2Y12 receptor blockers) has become the cornerstone of therapy for the management of acute and chronic coronary artery disease and the prevention of ischemic complications associated with percutaneous coronary intervention. However, dual antiplatelet therapy in primary prevention of cardiovascular disease in patients without known cardiovascular disease did not significantly reduce the risk of cardiovascular events, such as myocardial infarction, stroke or death, but significantly increased the rate of bleeding. Furthermore, despite multiple randomized controlled trials evaluating the efficacy and safety of aspirin use in patients without known cardiovascular disease, its role in primary prevention is still unclear, especially in patients with a higher risk of cardiovascular disease (non-diabetic individuals with >2 risk factors for coronary artery disease, elderly >60 years with additional risk factors, and patients with diabetes). Currently, there are four ongoing randomized controlled trials aiming to fill the missing gap in the efficacy and safety of aspirin therapy for primary prevention in these patients. The current European and United States Guidelines agree that primary prevention of cardiovascular disease is essential, but there are some substantial differences in risk estimation and treatment strategies among patients without known cardiovascular disease. This short review is focused on these differences and practical treatment approach to these patients based on present European and United States recommendations.

Novel Antiplatelet Agents in Cardiovascular Disease

2020 ◽  
Vol 25 (3) ◽  
pp. 191-200 ◽  
Author(s):  
Maximilian Tscharre ◽  
Alan D. Michelson ◽  
Thomas Gremmel
Keyword(s):  
Cardiovascular Disease ◽  
Antiplatelet Therapy ◽  
Animal Studies ◽  
Randomized Clinical Trials ◽  
Thrombus Formation ◽  
Antiplatelet Agents ◽  
Adenosine Diphosphate ◽  
Clinical Routine ◽  
New Agents ◽  
Antithrombotic Efficacy

Antiplatelet therapy reduces atherothrombotic risk and has therefore become a cornerstone in the treatment of cardiovascular disease. Aspirin, adenosine diphosphate P2Y12 receptor antagonists, glycoprotein IIb/IIIa inhibitors, and the thrombin receptor blocker vorapaxar are effective antiplatelet agents but significantly increase the risk of bleeding. Moreover, atherothrombotic events still impair the prognosis of many patients with cardiovascular disease despite established antiplatelet therapy. Over the last years, advances in the understanding of thrombus formation and hemostasis led to the discovery of various new receptors and signaling pathways of platelet activation. As a consequence, many new antiplatelet agents with high antithrombotic efficacy and supposedly only moderate effects on regular hemostasis have been developed and yielded promising results in preclinical and early clinical studies. Although their long journey from animal studies to randomized clinical trials and finally administration in daily clinical routine has just begun, some of the new agents may in the future become meaningful additions to the pharmacological armamentarium in cardiovascular disease.

Sign in / Sign up

Export Citation Format

Share Document